Prognosis of skin melanoma with regional node metastases (stage II)

Authors

  • Natale Cascinelli MD,

    Corresponding author
    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    • Istituto Nazionale Tumor, Via Venezian 1, 20133 Milan, Italy
    Search for more papers by this author
  • Maurizio Vaglini MD,

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author
  • Maurizio Nava MD,

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author
  • Mario Santinami MD,

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author
  • Raffaele Marolda MD,

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author
  • Dario Rovini MD,

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author
  • Claudio Clemente MD,

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author
  • Rossaria Bufalino,

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author
  • Alberto Morabito PhD

    1. Division of Surgical Oncology “E” and “H”, Division of Pathology and Cytology, and WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma, Istituto Nazionale Tumori, Milan, Italy
    Search for more papers by this author

Abstract

566 stage-II melanoma patients treated at the National Cancer Institute of Milan, Italy, were analyzed to evaluate the prognosis. Among the criteria considered, four were significantly associated with survival when considered as single factors: growth pattern, levels of invasion, the number of involved lymph nodes, and the extent of metastatic growth. As regards growth pattern, the observed 5-year survival rates were 41.9% for superficial spreading melanoma and 20.5% for nodular melanoma (P = 10−3). As regards levels, the 5-year survival rates were as follows: level II, 20.9%; level III, 33.1%; level IV, 43.2%; level V, 10.2% (P = 10−3). Patients with a partial node metastasis had 64.5% 10-year survival, while those with extension beyond the capsule had 32.6% 10-year survival (P = 10−9). Patients with one metastatic node had 43.4% 10-year survival, and patients with three or more positive nodes had 26.0% 10-year survival (P = 10−9). Multifactorial analysis shows that growth pattern and extent of node metastases significantly affect survival (P =10−2 and P = 10−4, respectively) while the number of involved nodes turns to borderline P-value (0.051) and the levels are no longer significant (P = 0.4).

Ancillary